Amneal’s generic version of Tobi inhalation solution approved by FDA

The FDA has approved Amneal Pharmaceuticals’s generic version of Tobi tobramycin inhalation solution, the company said. The product is the New Jersey-based generic pharmaceutical company’s first inhalation solution.

Amneal co-CEO and Chairman Chirag Patel said, “Tobramycin is extremely exciting for us in that it’s a new dosage form for Amneal—proof we’re delivering the varied portfolio we committed to offering our customers.”